Can sound waves supercharge immunotherapy against bile duct cancer?
NCT ID NCT07766187
First seen Aug 14, 2026 · Last updated Aug 14, 2026
Summary
This trial is testing whether adding a non-invasive ultrasound treatment called histotripsy to the immunotherapy drug durvalumab can strengthen the body's immune response against advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer. Histotripsy uses focused sound waves to destroy tumor tissue, which may release cancer antigens and boost the immune system. The study will enroll 12 people whose cancer is controlled after initial chemotherapy and immunotherapy, and will measure immune changes, safety, and how long the cancer stays controlled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- histotripsy (focused ultrasound) combined with durvalumab (immunotherapy)
- What this could lead to
- If successful, this combination could enhance the immune system's ability to fight bile duct cancer, potentially improving outcomes for patients with this difficult-to-treat disease.
- What could go wrong
- This is a small early-stage trial, so results may not apply broadly. The treatment could cause immune-related side effects or fail to boost the immune response as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
University of Wisconsin
Madison, Wisconsin, 53706, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
- Can matching drugs to tumor genes beat biliary cancer?
- Can freezing tumors boost immunotherapy in hard-to-treat bile duct cancers?
- Triple attack on bile duct cancer: chemo, targeted drug, and immunotherapy aim to make the inoperable operable
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?